Agios Pharmaceuticals Obtains $78,000,000 Series C Round

  • Feed Type
  • Date
    11/17/2011
  • Company Name
    Agios Pharmaceuticals
  • Mailing Address
    38 Sidney Street 2nd Floor Cambridge, MA 02139-4169
  • Company Description
    Agios is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth.
  • Website
    http://www.agios.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $78,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.
  • M&A Terms
  • Venture Investor
    Celgene Corporation
  • Venture Investor
    Flagship Ventures
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Third Rock Ventures